Hisamitsu Pharmaceutical : Announcement of Investment in GAIA Biomedicine, a Bio-Venture from Kyushu University in Japan
September 21, 2021 at 02:12 am EDT
Share
This material is an English translation of the press release announced on Sep 21, 2021 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Sep 21, 2021
Announcement of Investment in GAIA Biomedicine, a Bio-Venture from Kyushu University in Japan
Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President
and CEO: Kazuhide Nakatomi, hereinafter referred to as "Hisamitsu") is pleased to announce
that GAIA BioMedicine, Inc.,(Head Office: Shinjuku-ku, Tokyo, President: Kazuyuki Kuramori, hereinafter referred to as "GAIA Biomedicine"), a bio-venture company originating from Kyushu University, underwrote a third-party allocation of new shares and invested approximately 200 million yen in the company.
GAIA Biomedicine is a bio-venture company originating from Kyushu University that is working on novel cellular pharmaceuticals by utilizing the research results of Professor Yoshikazu Yonemitsu at the Graduate School of Pharmaceutical Sciences, Kyushu University. GAIA-102, which is being developed by GAIA Biomedicine, is an NK cell-likeCD3-negative cell that is expected to exhibit extremely high cytotoxicity against solid tumors.
GAIA Biomedicine 's business is expected to fulfill unmet medical needs and is expected to lead to the development of new business areas for Hisamitsu Pharmaceutical, which is why we have decided to invest in the company.
Hisamitsu Pharmaceutical will conduct business activities based on the technologies and know-how it has cultivated over the years, and will also utilize means such as partnering with other companies and M&A to create new value that has never been seen before. In the future, we will also utilize partnerships with other companies and M&A to create new value.
【Overview of GAIA BioMedicine, Inc.,】
Company name
GAIA BioMedicine, Inc.,
Business Description
Development of regenerative medicine and other products
Location
1-8,Tsugudo-cho,Shinjuku-ku, Tokyo
Date of establishment
October 2015
Representative
Kazuyuki Kuramori, President and Representative Director
URL
https://gaia-biomed.com/
Attachments
Original document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 06:11:04 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
